FOLH1 and prostate cancer: For example, a CNN-based model was developed by Lindgren Belal et al., detecting prostatic lesions in 660 PSMA PET/CT scans in patients with newly diagnosed prostate cancer or suspected to have recurrence after treatment with an average sensitivity of 79% [24] (Table 1), comparable with expert review.